Posted by Michael Wonder on 21 Mar 2022
EMA publishes agenda for 21-24 March CHMP meeting
21 March 2022 - The EMA has published a draft agenda for this week's CHMP meeting.
The CHMP is due to issue opinions for the following technologies:
- Amifampridine phosphate
- Leuprorelin mesylate
- Ciltacabtagene autoleucel
- Tixagevimab and cilgavimab
- Arimoclomol citrate
- Doxorubicin hydrochloride
